AI Platform Licensing with Johnson & Johnson
This agreement granted Janssen access to XtalFold, a proprietary AI-based software suite that provides rapid and accurate structural insights to accelerate biologics innovation across multiple phases.
PARTNERING
Innovating together to create transformative medicines
- 01 VALUE
Uniting Our Expertise
Building better therapies for patients is at the heart of every partnership we form. We collaborate closely with our partners to pursue transformative therapeutic differentiation without compromise. Our AI-powered platform has been recognized as a critical enabler in best-in-class drug design and development, helping turn ambitious ideas into realities.
We collaborate with life science innovators around the globe, from multinational pharmaceutical companies and clinical-stage biotech to early-stage startups and venture capitalists. By addressing real-world bottlenecks and de-risking critical stages of development, we co-create next-generation antibodies against challenging targets.
- 02 PRINCIPLE
Our Collaboration Principles
Pragmatic approach
We take a results-driven approach—rooted in validated technologies and data-informed decision-making, delivering reliable antibody drug design in a competitive timeline.
Multiple shots on goal
For high-stakes, high-potential programs, i.e., “must-win” opportunities, we pursue multiple complementary strategies to increase the likelihood of success.
End-to-end collaboration
We leverage our deep, cross-functional expertise that spans the entire biologics discovery process, fostering partner's long-term success in an evolving therapeutic landscape.
- 03 HIGHLIGHT
Example Collaborations
AI Platform Licensing with UCB
“UCB have a strong legacy of antibody discovery and engineering. We have established unique and powerful single-B cell screening and in vitro display discovery technologies to support hit identification and are pioneers in structure-based and computer-aided optimisation of molecules. The XtalFold™ license takes this further, integrating antibody-antigen structural insights into the entire antibody discovery and optimisation workflow.”
Daniel Lightwood, Head of Antibody Discovery and Optimisation, UCB
Drug Discovery with Pear Bio
“We have a running collaboration with Ailux on a novel immuno-oncology target. The entire team of Ailux engaged in our drug discovery program is very knowledgeable, experienced, and understanding. I would highly recommend Ailux for biologics drug discovery on novel targets.”
Chandan Seth Nanda, VP of Target & Drug Discovery, Pear Bio
- 04 PARTNERING
Innovate together to build transformative medicines.
